SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Thompson Falls, MT.

United States Antimony Corp.

United States Antimony Corp

United States Antimony Corp (UAMY) is trending as its new joint venture with Americas Gold and Silver for a state-of-the-art hydromet plant and a crucial DLA contract highlight its role in securing domestic critical mineral supply. The community is keenly observing its potential amidst government initiatives to reduce foreign dependency, even as discussions about market manipulation and short selling persist.

Evommune, Inc. is a clinical-stage biotechnology company. It engages in the development of medicines for inflammatory diseases. The company was founded by Luis C. Pena, Eugene Andrew Bauer, and Hans Hofland in 2020 and is headquartered in Palo Alto, CA.

Evommune Inc.

Evommune Inc

Evommune (EVMN) is experiencing a surge following positive top-line data from its Phase 2a trial for EVO301 in moderate-to-severe atopic dermatitis, leading to active community discussions around its potential and contributing to a broader biotech sector rally.

Salesforce, Inc. engages in the design and development of cloud-based enterprise software for customer relationship management. Its solutions include sales force automation, customer service and support, marketing automation, digital commerce, community management, collaboration, industry-specific solutions, and salesforce platform. The firm also provides guidance, support, training, and advisory services. The company was founded by Marc Russell Benioff and Parker Harris in 1999 and is headquartered in San Francisco, CA.

Salesforce Inc

Salesforce is caught in a market-wide software sector sell-off, with intense debate among investors over whether AI advancements pose an existential threat to its core business or if the stock is now massively oversold, presenting a generational buying opportunity given its strong fundamentals and significant buyback potential.

Fiserv, Inc. engages in the provision of financial services technology. It operates through the Merchant and Financial segments. The Merchant segment offers commerce-enabling products and services including merchant acquiring and digital commerce and mobile payment services, and security and fraud protection, stored-value, and pay-by-bank solutions to companies of all sizes. The Financial segment provides products and services such as processing of customer loan and deposit accounts, digital payments, and card transactions to financial institutions and corporate and public sector clients. The company was founded by Leslie M. Muma and George D. Dalton on July 31, 1984 and is headquartered in Milwaukee, WI.

Fiserv, Inc.

Fiserv is a trending topic following its recent earnings, which included a revenue miss but an EPS beat, sparking a community debate between those who see it as an undervalued fintech player with a promising management turnaround plan and others concerned about its debt, shrinking margins, and the broader industry's vulnerability to AI.

Datadog, Inc. engages in the development of a monitoring and analytics platform for developers, information technology operations teams and business users. Its platform integrates and automates infrastructure monitoring, application performance monitoring and log management to provide real-time observability of its customers' entire technology stack. The company was founded by Olivier Pomel and Alexis Lê-Quôc on June 4, 2010 and is headquartered in New York, NY.

Datadog Inc - Ordinary Shares - Class A

Datadog Inc

Datadog's strong Q4 earnings beat is sparking investor conversation, contrasting with softer full-year guidance that has some questioning its valuation and competitive landscape. The market is debating whether its AI-driven growth can lead a broader software sector rebound, or if recent sell-offs reflect ongoing headwinds.

Oscar Health, Inc. is a health insurance company, which serves its customers through a technology platform. It offers individual and family, small group and medicare advantage plans, and technology platform to others within the provider and payor space. The company was founded by Mario Tobias Schlosser, Kevin Nazemi, and Joshua Kushner on October 25, 2012 and is headquartered in New York, NY.

Oscar Health Inc - Ordinary Shares - Class A

Oscar Health is trending as its latest earnings report revealed a wider Q4 loss, yet this is largely overshadowed by strong 2026 profitability guidance and record membership growth. Community sentiment is divided between optimism for market share expansion and skepticism regarding the ambitious future projections in a volatile healthcare sector.

Jumia Technologies AG engages in the provision of logistic services. It operates a pan-African e-commerce platform. It operates through the following geographical segments: West Africa, North Africa, East and South Africa, Europe, United Arab Emirates, and Others. The company was founded by Jeremy Hodara, Sacha Poignonnec, Peter Allerstorfer, Manuel Koser, Tunde Kehinde, and Raphael Afaedor in 2012 and is headquartered in Berlin, Germany.

Jumia Technologies Ag - ADR

Jumia Technologies is trending following a strong earnings report that showcased robust revenue and GMV growth, significantly reduced cash burn, and a clear path to profitability by late 2026. The community is buzzing about this financial turnaround and recent analyst upgrades touting Jumia as the "Amazon of Africa" in an accelerating e-commerce market.

Spotify Technology SA engages in the provision of digital music services. It operates through the Premium and Ad-Supported segments. The Premium segment provides subscribers with online and offline streaming access of music and podcasts on computers, tablets, and mobile devices. The Ad-Supported segment offers users with limited on-demand online access of music and unlimited online access of podcasts on computers, tablets, and mobile and smart devices. The company was founded by Daniel Ek and Martin Lorentzon on December 27, 2006 and is headquartered in Luxembourg.

Spotify Technology S.A.

Spotify is trending following an impressive earnings beat, robust subscriber growth, and strong guidance, which has prompted multiple analyst upgrades and fueled community excitement for a significant rebound. Despite ongoing competitive pressures and recent price adjustments, investors are focusing on improved profitability and potential for a sustained upside.

Credo Technology Group Holding Ltd. engages in the development of connectivity solutions and products for the data infrastructure market. Its products include integrated circuits, active electrical cables, and SerDes chiplets. The company was founded by Chi Fung Cheng and Yat Tung Lam on 2008 and is headquartered in George Town, Cayman Islands.

Credo Technology Group Holding Ltd

Credo Technology Group is trending after pre-announcing preliminary revenue significantly above prior guidance, signaling accelerating demand from hyperscale customers and AI networking. The community is highly bullish, viewing this strong beat as validation for its critical role in the ongoing AI infrastructure build-out.

Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit. The company was founded in 1990 and is headquartered in San Francisco, CA.

Nektar Therapeutics

Nektar Therapeutics is generating significant buzz following strong positive maintenance data for its rezpegaldesleukin in atopic dermatitis, with the community actively discussing its potential as a game-changer against competitors and fueling buyout speculation amidst an ongoing lawsuit with Lilly, all while eagerly anticipating upcoming alopecia areata trial results.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

USM's Q2 Earnings Beat Estimates Despite Lower Revenues

USM's earnings beat estimates in the second quarter, with strong momentum in the tower business. Decline in prepaid and postpaid connections hindered growth.

U.S. Cellular (USM) Reports Q2 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for U.S. Cellular (USM) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

United States Cellular (USM) Surpasses Q2 Earnings and Revenue Estimates

U.S. Cellular (USM) delivered earnings and revenue surprises of +9.09% and +1.31%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Cogent Communications (CCOI) Reports Q2 Loss, Beats Revenue Estimates

Cogent (CCOI) delivered earnings and revenue surprises of -30.11% and +0.28%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

U.S. Cellular (USM) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates

Besides Wall Street's top-and-bottom-line estimates for U.S. Cellular (USM), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2025.

T-Mobile (TMUS) Q2 Earnings and Revenues Beat Estimates

T-Mobile (TMUS) delivered earnings and revenue surprises of +5.58% and +0.77%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

According to Goldman Sachs Research, a 5% increase in the tariff rate is estimated to reduce S&amp;P 500 earnings per share by 1-2%. The recently considered tariffs have reduced Goldman Sachs' S&amp;P 500 EPS forecasts by roughly 2-3%.&nbsp; Growth stocks are beaten down as recent tariffs triggered a sharp sell-off, with all major indexes, including the Dow Jones Industrial Average (DJI), S&amp;P 500 (SPX), and NASDAQ Composite (IXIC), falling significantly. The impact of US tariffs on the stock market is significant. &nbsp;Historically, the S&amp;P 500 has fallen by 5-7% when the US announced tariffs, as seen in 2018-2019. However, history suggests the downturn was temporary as it caused disruptions, but markets rebounded after the Phase I trade deal. Despite this, like energy, US manufacturers, Biotechnology, and Financials may benefit. As we navigate the current market landscape, let’s take a closer look at 5 stocks across various industries that are not prone to tariff uncertainty and present attractive buying opportunities. Shuttle Pharmaceuticals (SHPH) Shuttle Pharmaceuticals (NASDAQ: SHPH) is a specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy. The company is developing innovative radiation sensitizers, including its lead candidate Ropidoxuridine, to enhance the effectiveness of radiation therapy and bring new treatments to patients with cancer. Phase 2 Clinical Trial for Ropidoxuridine: The company is currently conducting a Phase 2 clinical trial for Ropidoxuridine to treat glioblastoma, a deadly form of brain cancer. The trial is designed to evaluate the safety and efficacy of Ropidoxuridine in combination with radiation therapy. The company has also completed a public offering of $5.75 million to fund its Phase 2 clinical trial, marketing efforts, and general corporate expenses. &nbsp;Expanding its Pipeline: Shuttle Pharmaceuticals is also developing other oncology drug candidates, including SP-2-225 and SP-1-303, which are in the preclinical stages of development. These candidates have the potential to treat a range of cancers, including breast, lung, and prostate cancer. Building Strategic Partnerships: The company is building strategic partnerships with leading cancer centers and research institutions to advance its research and development programs.&nbsp; While Shuttle Pharmaceuticals may not be directly impacted by tariffs, the company may benefit from the Trump administration’s efforts to promote domestic pharmaceutical manufacturing and reduce reliance on foreign imports. The administration is also expected to increase funding for cancer research, which could benefit Shuttle Pharmaceuticals and other companies developing innovative cancer treatments.Kinsale Capital (KNSL) Kinsale Capital (NYSE: KNSL) is a leading excess and surplus lines insurance provider that operates various business segments, including commercial property insurance. The company has a strong presence in the US and is poised for growth, driven by its strategic initiatives and market demand. Expanding Product Lines: Kinsale is continuously expanding its product lines and has recently launched a new agribusiness underwriting unit focused on farm and ranch exposures. Disciplined Underwriting: Kinsale maintains a disciplined approach to underwriting by focusing on high-margin opportunities and managing risks effectively. The company is investing in technology to drive cost efficiencies. Increased Demand: Kinsale’s expanded product lines, strategic underwriting, and focus on high-margin opportunities will drive growth in demand for its insurance products. Strong Financial Metrics: Kinsale has a solid balance sheet, a high cash conversion rate, and a well-diversified investment portfolio that will support its growth and profitability. &nbsp;United States Steel (X) United States Steel (NYSE: X) is a major player in the steel industry, with a strong presence in the United States and a history of innovation and adaptation. The company is expected to benefit from the recent announcement by President Trump to double the tariffs on Canadian steel and aluminum to 50%. Increased Demand and Pricing Power: The company will likely have higher demand, more pricing power, and reduced competition as imports from Canada become more expensive and reduce competition, allowing it to gain market share and increase its revenue. &nbsp;Improving Asset Turnover and Margins: United States Steel is focused on optimizing its operations and improving its asset turnover, with a goal of increasing its return on capital and reducing its costs. Investing in Strategic Projects: United States Steel is investing in new projects, such as the Big River Steel mill, to increase its production capacity and improve its competitiveness. &nbsp;Partnering with Other Companies: The company is exploring partnerships with other companies, such as Nippon Steel, to share technology and expertise and improve its operations. United States Cellular (USM) United States Cellular (NYSE: USM) is a leading telecommunications company providing wireless services to customers across the United States. The company is focusing on expanding its 5G network infrastructure, particularly in rural areas, through partnerships. Upgrading its 5G Network Infrastructure: United States Cellular has partnered with Ericsson to upgrade its 5G network infrastructure in rural areas by leveraging Ericsson’s advanced cell-site router technology to provide efficient transport infrastructure for mid-band spectrum deployment.&nbsp; &nbsp;Monetizing its Spectrum Holdings: United States Cellular has recently made deals to sell select spectrum assets to AT&amp;T and other mobile network operators. The company has agreed to sell a portion of its retained spectrum licenses to AT&amp;T for $1. billion and has also reached definitive deals to monetize around 70% of its total spectrum holdings (excluding mmWave). Financial Performance and Guidance: The company reported Q4 non-GAAP EPS of $0.05 and revenue of $970 million, which beat estimates by $5.3 million. Spectrum Portfolio And Future Plans: After the proposed sales, UScellular will be left with 1.86 billion MHz-Pops of low and mid-band spectrum, as well as 17.2 billion MHz-Pops of mmWave spectrum, with the substantial majority of retained value in the C-band spectrum. Plains GP (PAGP) Plains GP (NASDAQ: PAGP) is a midstream oil and gas company with diversified operations, primarily in crude oil. The company also owns an indirect, non-economic controlling interest in Plains All American Pipeline, a Master Limited Partnership focused on oil and gas midstream operations. Expanding its Asset Base Through Bolt-On Acquisitions: Plains GP has recently completed several acquisitions, including the Ironwood Midstream Energy acquisition and the purchase of the remaining 50% interest in Midway Pipeline, to strengthen its integrated asset base. &nbsp;Increasing Quarterly Distribution: The company has announced a 20% increase in its quarterly distribution, bringing the annualized distribution to $1.52 per unit, and plans to continue increasing the dividend by at least $0.15 per year with a 160% coverage. Investing in Growth Capital Expenditure: Plains GP plans to invest around $400 million annually in growth capex, including investments in Permian JV improvements to drive growth and increase earnings. Optimizing its Assets and Operations: The company is focused on optimizing its assets and operations, including increasing utilization of Corpus Christi-bound assets and growing Permian crude production to drive growth and increase efficiency. &nbsp;Conclusion While all the companies discussed present strong growth potential, Shuttle Pharmaceuticals stands out as a unique investment opportunity. As a US-based company with a domestic supply chain, it is insulated from trade-related disruptions. Moreover, its cutting-edge approach to cancer treatment, ongoing clinical trials, and strategic partnerships position it for substantial growth in the biotech sector.&nbsp; Read Next: Why This Electric Vehicle Market Player’s Proprietary Battery-Swapping Technology is a Game-Changer Our email list eats first! Get exclusive alerts on explosive stock picks like AST SpaceMobile (NASDAQ: ASTS), which shot up +533% after our profile. Get our email signals based on our proprietary 5-indicator system before any of our other platforms by clicking here. Join the Discussion in the WVC Facebook Investor Group Do you have a stock tip or news story suggestion? Please email us at Invest@WealthyVC.com. &nbsp;This report/release/profile is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below. Wealthy VC and its employees are not Registered Investment Advisors, Broker-Dealers or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Wealthy VC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled through their website, news releases, and corporate filings, or is available from public sources and Wealthy VC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. Our website and newsletter are for entertainment purposes only. This website is NOT a source of unbiased information. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. &nbsp;Release of Liability: Through the use of this email and/or website advertisement, by viewing or using it, you agree to hold Wealthy VC, its operators, owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. Wealthy VC-sponsored advertisements do not purport to provide an analysis of any company’s financial position, operations or prospects and this is not to be construed as a recommendation by Wealthy VC or an offer or solicitation to buy or sell any security. WealthyVC and our controlling entity 1000724287 Ontario Ltd have been compensated USD $7,500 per month for six months for investor relations by Shuttle Pharmaceuticals Holdings, Inc. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provided herein. Instead, Wealthy VC strongly urges you to conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D and all reports published on SEDAR if the company featured is Canadian. Wealthy VC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled. The Private Securities Litigation Reform Act of 1995 provides investors with a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be “forward-looking statements”. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions “may”, “could”, or “might” occur. Understand there is no guarantee past performance will be indicative of future results. Past Performance is based on the security’s previous day’s closing price and the high of-day price during our promotional coverage. In preparing this publication, Wealthy VC has relied upon information supplied by various public sources and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this email and website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this email and website are believed to be reliable, however, Wealthy VC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of material facts from such advertisement. Wealthy VC is not responsible for any claims made by the companies advertised herein, nor is Wealthy VC responsible for any other promotional firm, its program or its structure. <a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/disclaimer/">View Full Disclaimer</a>&nbsp;

In this photo illustration, the Kinsale Capital Group logo is displayed on a smartphone screen

Growth Stocks Are Beaten Down. Why It’s Temporary and What Should Be On Your Shopping List Instead

According to Goldman Sachs Research, a 5% increase in the tariff rate is estimated to reduce S&P 500 earnings per share by 1%-2%

Others

Shares of U.S. Cellular (<a class="mention" data-mention="$USM" data-symbol-id="USM" href="https://stocktwits.com/symbol/USM" target="_blank">$USM</a>) and Telephone and Data Systems (<a class="mention" data-mention="$TDS" data-symbol-id="TDS" href="https://stocktwits.com/symbol/TDS" target="_blank">$TDS</a>) surged Thursday following an upbeat note from Raymond James, which upgraded both stocks to ‘Outperform’ from ‘Market Perform.’&nbsp;The firm set price targets of $86 for U.S. Cellular, implying a 32% upside, and $51 for TDS, signaling a potential 56% upside based on Wednesday’s closing prices.Raymond James analyst Ric Prentiss pointed to the outcome of the 2024 U.S. Presidential election, speculating that a Trump victory could create a more favorable regulatory environment.&nbsp;This, he believes, could clear the path for T-Mobile’s (<a class="mention" data-mention="$TMUS" data-symbol-id="TMUS" href="https://stocktwits.com/symbol/TMUS" target="_blank">$TMUS</a>) $4.4 billion acquisition of U.S. Cellular to proceed. The deal is expected to close mid-2024.“We see significant upside in shares of both stocks given the ongoing strategic review and announced asset sales at USM, and now feel the regulatory path to approval is cleaner and timeline should be better,” he wrote in a Thursday note.&nbsp;Prentiss also noted that U.S. Cellular, through ongoing strategic reviews and asset sales, may be on track to transition into a standalone tower company, which could lead to a much higher multiple in the future.&nbsp;In a separate announcement, U.S. Cellular said on Thursday it agreed with AT&amp;T (<a class="mention" data-mention="$T" data-symbol-id="T" href="https://stocktwits.com/symbol/T" target="_blank">$T</a>) to sell a portion of its retained spectrum licenses for $1.018 billion, part of a strategy to opportunistically monetize spectrum not included in its proposed sale to T-Mobile (TMUS).&nbsp;It follows a previous deal, announced last month, to sell a portion of these licenses to Verizon (<a class="mention" data-mention="$VZ" data-symbol-id="VZ" href="https://stocktwits.com/symbol/VZ" target="_blank">$VZ</a>) and two other mobile network operators.Both stocks have seen impressive gains in 2024, with U.S. Cellular up nearly 57% year-to-date and TDS rising more than 77%. Over the past six months, the stocks have surged around 83% and 111%, respectively.For updates and corrections, email&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="mailto:newsroom@stocktwits.com">newsroom@stocktwits.com</a>Read next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/cyn-stocks-rises-after-q3-earnings/cJ4P6qRRa4">Cyngn Stock Soars Pre-Market On Q3 Win, Nvidia-Powered Advancements: Grabs Retail’s Attention</a>

Trump's win could clear the path for T-Mobile’s ($TMUS) $4.4 billion acquisition of U.S. Cellular to proceed, the analyst feels.

Are USM, TDS Trump Trades Now? Raymond James Upgrades Mid-Cap Telecom Stocks On Reduced Regulatory Risk 

The analyst noted that U.S. Cellular, through ongoing strategic reviews and asset sales, may be on track to transition into a standalone tower company.

Equity

United States Cellular Corporation (USM) <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/uscellular-announces-sale-of-select-spectrum-assets-for-1-0-billion-302279983.html">said</a> on Friday it has entered into an agreement with Verizon Communications Inc. (VZ) to sell a portion of the firm’s retained spectrum licenses for total consideration of $1 billion.At the same time, US Cellular has also entered into agreements with two other mobile network operators for the sale of other selected spectrum licenses. The company said the transactions are part of its objective to monetize the spectrum that was not included in the proposed sale to T-Mobile.CEO Laurent C. Therivel said the firm is continuing the process to opportunistically monetize the remaining spectrum assets not included in Friday’s announcement. Shares of USM rose over 10% on Friday morning after the announcement.As per the agreement, Verizon will sell 663 million MHz POPs of its cellular (850 MHz) spectrum licenses as well as 11 million MHz POPs of its AWS and 19 million MHz POPs of its PCS licenses for a total of $1 billion. The purchase price is payable in cash and subject to certain potential adjustments specified in the purchase agreement.US Cellular has also reached agreements to sell a total of 12 million MHz POPs of its spectrum licenses across the CBRS, C-Band, and 700 MHz B/C Block bands to two additional mobile network operators.CEO Therivel highlighted that a significant value for a portion of the remaining licenses will be realized. “…these agreements with multiple mobile network operators ensure that this spectrum will be put to work for consumers throughout the country,” he said.Following the announcement, retail sentiment on Stocktwits for USM stock jumped into the ‘extremely bullish’ territory (84/100) from the ‘bearish’ zone a day ago.<figure class="image"><a href="https://stocktwits.com/symbol/USM"><img style="aspect-ratio:1862/524;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_10_18_at_9_49_58_AM_461447e256.png" alt="USM sentiment meter as of 9:30 a.m. ET on Oct. 18, 2024 | Source: Stocktwits" width="1862" height="524"></a><figcaption>USM sentiment meter as of 9:30 a.m. ET on Oct. 18, 2024 | Source: Stocktwits</figcaption></figure>USM shares have gained over 52% since the beginning of the year while VZ shares have returned over 12% during the period.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/ally-financial-shares-fall-premarket-after-q3-report/cJ22j2rRIF">Ally Financial Shares Fall Premarket After Q3 Earnings Report: Retail Ignores Market Pessimism</a>For updates and corrections email newsroom@stocktwits.com

USM shares have gained over 52% since the beginning of the year | Representative Image Source: Pexels

United States Cellular Stock Jumps 10% After Spectrum Deal With Verizon: Retail Cheers On

CEO Laurent C. Therivel said the firm is continuing the process to opportunistically monetize the remaining spectrum assets not included in Friday’s announcement

Array Digital Infrastructure, Inc. engages in the provision of wireless telecommunication services. It operates through the Wireless and Towers segments. The Wireless segment uses company-owned towers to locate its network equipment, using estimated market pricing. The Towers segment records rental revenue. The firm’s products include smartphones, tablets, vehicle routers, and accessories. It offers Internet plans, prepaid & postpaid plans, and roaming services. The company was founded by Leroy T. Carlson in 1983 and is headquartered in Chicago, IL.

Array Digital Infrastructure Inc.

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $HOOD earnings on Tuesday?

USM
United States Cellular Corporation

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest USM News

USMUnited States Cellular Corporation